Compare UNP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNP | VRTX |
|---|---|---|
| Founded | 1862 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.7B | 115.7B |
| IPO Year | N/A | 1991 |
| Metric | UNP | VRTX |
|---|---|---|
| Price | $232.00 | $478.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 27 |
| Target Price | $259.04 | ★ $509.17 |
| AVG Volume (30 Days) | ★ 2.7M | 1.3M |
| Earning Date | 01-27-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 8.28 | N/A |
| EPS | 11.78 | ★ 14.22 |
| Revenue | ★ $24,546,000,000.00 | $11,723,300,000.00 |
| Revenue This Year | $2.26 | $10.93 |
| Revenue Next Year | $3.52 | $8.44 |
| P/E Ratio | ★ $19.49 | $32.93 |
| Revenue Growth | 1.06 | ★ 10.33 |
| 52 Week Low | $204.66 | $362.50 |
| 52 Week High | $256.84 | $519.68 |
| Indicator | UNP | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 62.38 |
| Support Level | $219.98 | $429.00 |
| Resistance Level | $233.68 | $472.58 |
| Average True Range (ATR) | 4.98 | 13.74 |
| MACD | 0.12 | 1.07 |
| Stochastic Oscillator | 77.21 | 82.72 |
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two-thirds of the US, Union Pacific generated $24 billion of revenue in 2024 by hauling coal, industrial products, intermodal containers, agricultural goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one-fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.